Hermetica Superfood Encyclopedia
The Short Answer
D-Limonene (R-(+)-limonene) is a cyclic monoterpene found abundantly in citrus peel oil that exerts anticancer and anti-inflammatory effects primarily by modulating Ras protein prenylation, suppressing cyclin D1 expression, and activating apoptotic pathways. It concentrates preferentially in fatty tissues, including breast tissue, making it a candidate adjuvant in oncology research.
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelModerate
Primary KeywordD-Limonene benefits
Synergy Pairings5
D-Limonene (R-(+)-limonene) — botanical close-up
Health Benefits
Origin & History
Natural habitat
D-Limonene is a naturally occurring monoterpene hydrocarbon found primarily in citrus essential oils, with the highest concentrations in orange, lemon, and grapefruit peels. It is extracted through cold pressing or steam distillation of citrus rinds, yielding a cyclic monoterpene with the formula C10H16.
“No traditional medicine uses were documented in the research provided. Current applications are based entirely on modern preclinical and clinical cancer research rather than historical ethnomedical systems.”Traditional Medicine
Scientific Research
Clinical evidence is limited to small phase I/II trials, including a phase I study (n=32, PMID: 9654110) establishing MTD at 8 g/m²/day with one partial response in breast cancer, and a phase II trial (n=43) showing breast tissue accumulation and cyclin D1 reduction. No randomized controlled trials or meta-analyses on D-limonene alone were identified.
Preparation & Dosage
Traditional preparation
Clinically studied doses range from 0.5-12 g/m²/day in cancer trials, with maximum tolerated dose at 8 g/m²/day (approximately 400-600 mg/kg). Breast tissue studies used 2 g/day for 2-6 weeks. Only pharmaceutical-grade pure D-limonene was studied, not standardized extracts. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
D-Limonene is a pure monocyclic monoterpene compound (C10H16, molecular weight 136.23 g/mol), not a nutritional food source, so conventional macronutrient/micronutrient framing does not apply. Bioactive compound content: essentially 100% R-(+)-limonene enantiomer when in purified form. Naturally occurs in citrus peel oils at concentrations of 40,000–960,000 mg/kg (40–96% of essential oil composition depending on species); orange peel oil contains approximately 680,000–960,000 mg/kg, lemon peel oil approximately 400,000–700,000 mg/kg. Caloric density as a lipophilic terpene is approximately 8.8 kcal/g (theoretical, as a hydrocarbon), but dietary exposure doses are typically 1–10 g/day in supplemental form, contributing negligible calories in practical use. Contains no protein, carbohydrates, fiber, vitamins, or minerals. Key bioactive properties stem from its monoterpene structure: highly lipophilic (log P ≈ 4.57), enabling strong tissue partitioning — confirmed breast tissue concentration of 41.3 μg/g at supplemental doses of ~2 g/day in human phase II data. Bioavailability: rapidly absorbed orally, undergoes hepatic metabolism to perillic acid, dihydroperillic acid, uroterpenol, and limonene-1,2-diol via CYP450 enzymes (primarily CYP2C19, CYP3A4); urinary metabolite perillic acid reaches plasma concentrations of approximately 30–50 μM at 2 g/day dosing. Half-life approximately 12–24 hours. No dietary fiber, no mineral content, no vitamin content.
How It Works
Mechanism of Action
D-Limonene inhibits the post-translational prenylation of Ras and other small G-proteins by blocking farnesyl pyrophosphate transferase and geranylgeranyl transferase enzymes, disrupting downstream MAPK and PI3K/Akt proliferation signaling. It downregulates cyclin D1, a cell-cycle regulatory protein, thereby arresting tumor cells in G1 phase and reducing uncontrolled mitosis. Additionally, D-Limonene suppresses NF-κB activation and reduces pro-inflammatory cytokine production, including TNF-α and IL-6, contributing to its anti-inflammatory profile.
Clinical Evidence
A phase I dose-escalation trial in breast cancer patients demonstrated that oral D-Limonene produced one confirmed partial response lasting 11 months, establishing preliminary proof-of-concept for anticancer activity at tolerable doses. A subsequent phase II study (n=43) quantified tissue pharmacokinetics, confirming breast tissue concentrations of 41.3 μg/g and a statistically significant reduction in tumor cyclin D1 expression after supplementation. Evidence remains early-stage and limited to small trials without randomized placebo controls, so conclusions about efficacy must be considered preliminary. Anti-inflammatory effects have been documented in preclinical models but have not yet been confirmed in adequately powered human randomized controlled trials.
Safety & Interactions
D-Limonene is generally recognized as safe (GRAS) by the FDA at culinary doses and is well tolerated at supplemental doses up to approximately 1–2 g/day in clinical trials, with the most common adverse effects being mild gastrointestinal symptoms such as heartburn, nausea, and belching due to its esophageal sphincter-relaxing properties. Individuals with gastroesophageal reflux disease (GERD) or peptic ulcers should use caution, as it may exacerbate reflux symptoms. D-Limonene is metabolized by CYP1A2, CYP2C9, and CYP3A4 hepatic enzymes, creating a theoretical interaction risk with drugs dependent on these pathways, including warfarin, statins, and certain chemotherapeutics — though clinical interaction data in humans are lacking. Safety in pregnancy and lactation has not been established in controlled human studies, and use should be avoided in these populations without medical supervision.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
R-(+)-limoneneDextrolimonene(+)-LimoneneCitrus terpeneOrange peel oil monoterpene4-Isopropenyl-1-methylcyclohexeneCarveneCinene
Frequently Asked Questions
What dose of D-Limonene was used in cancer clinical trials?
Phase I breast cancer trials used escalating oral doses of D-Limonene typically ranging from 0.5 g to over 8 g per day to establish tolerability, with pharmacokinetic data collected across dose levels. The phase II study confirming breast tissue concentrations of 41.3 μg/g used doses in the gram-per-day range, though the optimal therapeutic dose remains undefined pending larger trials.
How does D-Limonene get into breast tissue so effectively?
D-Limonene is a lipophilic monoterpene, meaning it preferentially partitions into fat-rich tissues due to its high octanol-water partition coefficient. Breast tissue, being substantially composed of adipose, acts as a depot for D-Limonene after oral administration, explaining the measured concentration of 41.3 μg/g observed in the phase II clinical study. This pharmacokinetic property makes it particularly interesting for breast-related conditions compared to less lipophilic compounds.
Can D-Limonene help with acid reflux?
D-Limonene has been marketed for acid reflux relief at a dose of 1,000 mg every other day for 20 days, based on small pilot studies suggesting it may coat the esophageal mucosa and neutralize gastric acid through a d-limonene-gastric acid interaction. However, the evidence base is very limited — trials have been small and methodologically weak — so it should not replace established GERD treatments. Paradoxically, because it relaxes the lower esophageal sphincter, higher doses may worsen reflux in some individuals.
Does D-Limonene interact with any medications?
D-Limonene is metabolized by cytochrome P450 enzymes CYP1A2, CYP2C9, and CYP3A4, which are responsible for processing a large number of pharmaceuticals including warfarin, statins, benzodiazepines, and some chemotherapy agents. Competitive inhibition or induction of these enzymes by D-Limonene could theoretically alter plasma levels of co-administered drugs, though documented clinical case reports of interactions are currently lacking. Anyone taking medications with a narrow therapeutic index should consult a physician before supplementing with D-Limonene.
What foods are naturally high in D-Limonene?
D-Limonene comprises up to 90–95% of cold-pressed citrus peel essential oils, making orange peel oil, lemon peel oil, and grapefruit peel oil the richest dietary sources by far. Whole citrus fruit zest provides meaningful amounts — approximately 300–400 mg of D-Limonene per tablespoon of fresh orange zest — while the juice itself contains only trace quantities. Other sources include caraway seeds, dill, and celery, though at considerably lower concentrations than citrus peel.
What is the difference between D-Limonene and L-Limonene, and why does it matter?
D-Limonene (R-(+)-limonene) and L-Limonene are mirror-image enantiomers with identical chemical formulas but different three-dimensional structures. D-Limonene is the biologically active form found in citrus peels and has been studied in human cancer trials, while L-Limonene is the less common form with minimal research support. The body metabolizes and distributes these enantiomers differently, making D-Limonene specifically the form used in clinical research for potential anti-cancer and anti-inflammatory effects.
Is D-Limonene safe for long-term supplementation?
D-Limonene has demonstrated a favorable safety profile in clinical trials, with phase I and II studies showing no serious adverse events at studied doses. However, long-term safety data beyond several months of supplementation remains limited in humans, so extended use should be discussed with a healthcare provider. Some individuals may experience gastrointestinal symptoms or allergic reactions due to its potent volatile oil properties, particularly at higher doses.
Why does D-Limonene concentrate in breast tissue specifically rather than distributing evenly throughout the body?
D-Limonene demonstrates selective accumulation in breast tissue at concentrations significantly higher than in blood (41.3 μg/g in breast tissue versus lower systemic levels), though the exact biological mechanism for this preferential distribution is not fully elucidated. This tissue-specific concentration may relate to the high lipophilic (fat-loving) nature of D-Limonene and possible interactions with estrogen-responsive tissues. This property has made D-Limonene of particular interest in breast cancer research, as it achieves therapeutic levels in target tissue while potentially minimizing systemic exposure.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w d-limonene-limonene curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
